Vaccine Candidate for Porcine Encephalomyocarditis Virus
Author Information
Author(s): Jeoung Hye-Young, Lee Won-Ha, Jeong WooSeog, Shin Bo-Hye, Choi Hwan-Won, Lee Hee Soo, An Dong-Jun
Primary Institution: National Veterinary Research and Quarantine Service
Hypothesis
Can virus-like particles of porcine encephalomyocarditis virus provide immunogenicity and protective efficacy in pigs?
Conclusion
Recombinant EMCV VLPs could represent a new vaccine candidate to protect against EMCV infection in pig farms.
Supporting Evidence
- VLPs were successfully generated and confirmed to be approximately 30-40 nm in size.
- Immunization of mice with VLPs resulted in 90% protection from EMCV infection.
- Swine showed increased neutralizing antibody titers after immunization with VLPs.
- No severe injection site reactions were observed in swine after immunization.
- Neutralizing antibodies were maintained at high levels for weeks after the second immunization.
Takeaway
Scientists created a new type of vaccine using virus-like particles to help protect pigs from a harmful virus, and it worked well in tests.
Methodology
The study involved generating VLPs using a baculovirus expression system and testing their immunogenicity and protective efficacy in mice and swine.
Limitations
The study primarily focused on short-term immunogenicity and did not assess long-term effects or efficacy in field conditions.
Participant Demographics
Twelve pigs weighing approximately 30-40 kg each were used in the study.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website